Key Takeaways
- Cellevate AB has appointed Dr. Christel Fenge as Chief Technology Officer (CTO) to lead the company’s commercialization and scale-up efforts.
- Dr. Fenge brings over 30 years of experience in bioprocessing and biopharmaceutical industries, previously holding leadership roles at Cytiva and Sartorius.
- Her expertise will support Cellevate’s expansion of its nanofiber-based cell culture systems, which have demonstrated strong potential in large-scale biomanufacturing.
- The appointment strengthens Cellevate’s position as a key player in upstream bioprocessing, supporting strategic partnerships with customers and bioprocessing solution providers.
Cellevate Strengthens Leadership with Appointment of Dr. Christel Fenge as CTO
Bringing Extensive Bioprocessing Experience to Cellevate
Cellevate AB, a biotech company focused on next-generation cell culture solutions, has appointed Dr. Christel Fenge as Chief Technology Officer (CTO). Dr. Fenge has served as a Strategic Advisor to Cellevate since June 2024 and now joins the management team to drive commercialization and scale-up efforts.
With over three decades of leadership experience in bioprocessing and biopharmaceuticals, Dr. Fenge has held senior roles at Cytiva and Sartorius, where she led R&D, marketing, and product management efforts for upstream and downstream bioprocessing.
“I am delighted to take on the role of CTO at Cellevate. The company’s commercially available nanofiber-based cell culture systems have already shown great potential in biomanufacturing, and I look forward to supporting the team as we now have moved into commercialization and scale-up.” — Dr. Christel Fenge, CTO, Cellevate AB
Accelerating Commercialization of Nanofiber-Based Cell Culture Systems
Scaling Up for Large-Scale Biomanufacturing Applications
Cellevate is advancing nanofiber-based cell culture technology, which offers enhanced scalability and efficiency for bioprocessing applications. Dr. Fenge’s appointment aligns with the company’s strategy to:
- Expand commercial deployment of Cellevat3d® nanofiber cell culture systems.
- Support large-scale therapeutic applications in biomanufacturing.
- Strengthen partnerships with bioprocessing solution providers.
“Bringing Dr. Fenge into the management team strengthens our ability to accelerate commercialization and strategic partnerships with customers and turnkey solution providers in bioprocessing. Her deep expertise in upstream bioprocessing, combined with strategic leadership, will be invaluable as we continue to commercialize and implement Cellevat3d® nanofiber cell culture solutions in new therapeutic large-scale applications.” — Laura Chirica, CEO, Cellevate AB
